ConductScience.org, home

Paper20183916

Inhaled drug delivery for tuberculosis therapy.

Muttil P and 2 others. Pharm Res, 2009. Cited by 106 papers, by iCite.

Cite this record

ConductScience Library. Inhaled drug delivery for tuberculosis therapy. Papers, record 20183916. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20183916

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Inhaled drug delivery for tuberculosis therapy.
PubMed
Journal
Pharm Res
PubMed
Year
2009
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
Citations, by iCite
106
iCite
Relative citation ratio, by iCite
3.23
iCite
Revised in PubMed
2021-10-20
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Muttil PPavan
2Wang CChenchen
3Hickey AJAnthony J

Source PubMed

Download CSV of authors

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antitubercular AgentsMajor topic
Mycobacterium tuberculosisMajor topic
TuberculosisMajor topic
Administration, Inhalation
Humans

References118

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
12564468Prevention of Pneumocystis carinii pneumonia by inhaled pentamidine.Lancet1989https://conductscience.org/library/papers/2564468PubMed
218419443Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial.Clin Infect Dis2008https://conductscience.org/library/papers/18419443PubMed
316370941Aerosolised antibiotics: a critical appraisal of their use.Expert Opin Drug Deliv2006https://conductscience.org/library/papers/16370941PubMed
417173225Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients.Clin Infect Dis2007https://conductscience.org/library/papers/17173225PubMed
515608701Tuberculosis - metabolism and respiration in the absence of growth.Nat Rev Microbiol2005https://conductscience.org/library/papers/15608701PubMed
615680764Can laboratory reference strains mirror "real-world" pathogenesis?Trends Microbiol2005https://conductscience.org/library/papers/15680764PubMed
716362982New insights into the function of granulomas in human tuberculosis.J Pathol2006https://conductscience.org/library/papers/16362982PubMed
810985173Factors influencing response to treatment of pulmonary tuberculosis.Acta Med Okayama2000https://conductscience.org/library/papers/10985173PubMed
912636160Phagocytosis and phagosomal fate of surface-modified microparticles in dendritic cells and macrophages.Pharm Res2003https://conductscience.org/library/papers/12636160PubMed
1014613962Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.J Antimicrob Chemother2003https://conductscience.org/library/papers/14613962PubMed
1112901560Phagocytosis of synthetic particulate vaccine delivery systems to program dendritic cells.Expert Rev Vaccines2002https://conductscience.org/library/papers/12901560PubMed
1218658109Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.Am J Respir Crit Care Med2008https://conductscience.org/library/papers/18658109PubMed
1319139288Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation.Antimicrob Agents Chemother2009https://conductscience.org/library/papers/19139288PubMed
1415225870Nebulization of liposome encapsulated antitubercular drugs in guinea pigs.Int J Antimicrob Agents2004https://conductscience.org/library/papers/15225870PubMed
1516441433Characterization of the tuberculous granuloma in murine and human lungs: cellular composition and relative tissue oxygen tension.Cell Microbiol2006https://conductscience.org/library/papers/16441433PubMed
16785420Historical review of the use of parasympatholytic agents in the treatment of respiratory disorders.Postgrad Med J1975https://conductscience.org/library/papers/785420PubMed
1716113455The lungs as a portal of entry for systemic drug delivery.Proc Am Thorac Soc2004https://conductscience.org/library/papers/16113455PubMed
1815761077Antitubercular inhaled therapy: opportunities, progress and challenges.J Antimicrob Chemother2005https://conductscience.org/library/papers/15761077PubMed
197761379[Effectiveness of liposomal antibacterial drugs in the inhalation therapy of experimental tuberculosis].Probl Tuberk1995https://conductscience.org/library/papers/7761379PubMed
2013130011Tuberculosis in seals caused by a novel member of the Mycobacterium tuberculosis complex: Mycobacterium pinnipedii sp. nov.Int J Syst Evol Microbiol2003https://conductscience.org/library/papers/13130011PubMed

See all 118 referencesDownload CSV of references

Cited by38

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 106 citations.

PMIDTitleJournalYearIn PapersSource
42797339Engineering of OHet72 Nanocrystals into Nanostructured Microparticles for Pulmonary Delivery of a Novel Antitubercular Drug Candidate.Pharmaceutics2026https://conductscience.org/library/papers/42797339PubMed
42747544Inhalable Dry Powders of Antimicrobial Agents in Respiratory Diseases.Lung2026https://conductscience.org/library/papers/42747544PubMed
40487670Inhaled non-viral delivery systems for RNA therapeutics.Acta Pharm Sin B2025https://conductscience.org/library/papers/40487670PubMed
37590399Pharmacokinetic Considerations for Optimizing Inhaled Spray-Dried Pyrazinoic Acid Formulations.Mol Pharm2023https://conductscience.org/library/papers/37590399PubMed
36970149Multi-drug loaded eugenol-based nanoemulsions for enhanced anti-mycobacterial activity.RSC Med Chem2023https://conductscience.org/library/papers/36970149PubMed
36203881Recent Developments in Drug Delivery for Treatment of Tuberculosis by Targeting Macrophages.Adv Ther (Weinh)2022https://conductscience.org/library/papers/36203881PubMed
36131190A review of formulations and preclinical studies of inhaled rifampicin for its clinical translation.Drug Deliv Transl Res2023https://conductscience.org/library/papers/36131190PubMed
36114362Optimization and Scale Up of Spray Dried CPZEN-45 Aerosol Powders for Inhaled Tuberculosis Treatment.Pharm Res2022https://conductscience.org/library/papers/36114362PubMed
35583640LipNanoCar Technology - A Versatile and Scalable Technology for the Production of Lipid Nanoparticles.Adv Exp Med Biol2022https://conductscience.org/library/papers/35583640PubMed
35242137The COVID-19/Tuberculosis Syndemic and Potential Antibody Therapy for TB Based on the Lessons Learnt From the Pandemic.Front Immunol2022https://conductscience.org/library/papers/35242137PubMed
35112802
Nano-in-Microparticles for Aerosol Delivery of Antibiotic-Loaded, Fucose-Derivatized, and Macrophage-Targeted Liposomes to Combat Mycobacterial Infections: In Vitro Deposition, Pulmonary Barrier Interactions, and Targeted Delivery.
Adv Healthc Mater2022https://conductscience.org/library/papers/35112802PubMed
34959328Spray-Dried Powder Formulation of Capreomycin Designed for Inhaled Tuberculosis Therapy.Pharmaceutics2021https://conductscience.org/library/papers/34959328PubMed
34041715A triple combination 'nano' dry powder inhaler for tuberculosis: in vitro and in vivo pulmonary characterization.Drug Deliv Transl Res2021https://conductscience.org/library/papers/34041715PubMed
33214909The Role of Metallic Nanoparticles in Inhibition of Mycobacterium Tuberculosis and Enhances Phagosome Maturation into the Infected Macrophage.Oman Med J2020https://conductscience.org/library/papers/33214909PubMed
33049807A review on chitosan and its development as pulmonary particulate anti-infective and anti-cancer drug carriers.Carbohydr Polym2020https://conductscience.org/library/papers/33049807PubMed
31819421Rifampicin-Carbohydrate Spray-Dried Nanocomposite: A Futuristic Multiparticulate Platform For Pulmonary Delivery.Int J Nanomedicine2019https://conductscience.org/library/papers/31819421PubMed
31650321Why Wait? The Case for Treating Tuberculosis with Inhaled Drugs.Pharm Res2019https://conductscience.org/library/papers/31650321PubMed
31527037Prophylaxis of Mycobacterium tuberculosis H37Rv Infection in a Preclinical Mouse Model via Inhalation of Nebulized Bacteriophage D29.Antimicrob Agents Chemother2019https://conductscience.org/library/papers/31527037PubMed
31321552Development and Characterization of a Dry Powder Formulation for Anti-Tuberculosis Drug Spectinamide 1599.Pharm Res2019https://conductscience.org/library/papers/31321552PubMed
31152746A Spray-Dried Combination of Capreomycin and CPZEN-45 for Inhaled Tuberculosis Therapy.J Pharm Sci2019https://conductscience.org/library/papers/31152746PubMed

See all 38 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/20183916

GET https://conductscience.org/api/papers/v1/20183916/references?page=2